RT Journal Article
T1 Genetic variation in CCR2 and CXCL12 genes impacts on CD4 restoration in patients initiating cART with advanced immunesupression.
A1 Restrepo, Clara
A1 Gutierrez-Rivas, Mónica
A1 Pacheco, Yolanda M
A1 García, Marcial
A1 Blanco, Julià
A1 Medrano, Luz M
A1 Navarrete-Muñoz, María A
A1 Gutiérrez, Félix
A1 Miralles, Pilar
A1 Dalmau, David
A1 Gómez, Juan Luis
A1 Górgolas, Miguel
A1 Cabello, Alfonso
A1 Resino, Salvador
A1 Benito, José M
A1 Rallón, Norma
A1 CoRIS and the HIV Biobank integrated in the Spanish AIDS Research Network Project RIS/EPICLIN 10_2015, 
AB We investigated the association of genetic polymorphisms in chemokine and chemokine receptor genes with poor immunological recovery in HIV patients starting combined antiretroviral therapy (cART) with low CD4 T-cell counts. A case-control study was conducted in 412 HIV-infected patients starting cART with CD4 T-cell count  Thirty two percent (134/412) of patients were classified as INR. After adjusting by age, route of HIV infection, length of infection before cART and viral hepatitis coinfection, CCR2 rs1799864-AG genotype was significantly associated with INR status (OR [95% CI]: 1.80 [1.04-3.11]; p = 0.04), and CXCL12 rs1801157-TT genotype showed a trend (OR [95% CI]: 2.47 [0.96-6.35]; p = 0.06). CCR2 rs1799864-AG or CXCL12 rs1801157-TT genotypes influence on the probability of poor CD4 recovery in the population of HIV patients starting cART with low CD4 counts. Genotyping of these polymorphisms could be used to estimate the risk of poor CD4 restoration, mainly in patients who are diagnosed late in the course of infection.
YR 2019
FD 2019-03-28
LK http://hdl.handle.net/10668/13765
UL http://hdl.handle.net/10668/13765
LA en
DS RISalud
RD Apr 19, 2025